Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Bamboos Health Care Holdings Ltd (2293) AI Stock Analysis

HK:2293

Bamboos Health Care Holdings Ltd

(HKEX:2293)

Select Model
Rating:51Neutral
Price Target:HKD 0.39â–¼(-4.44% Downside)
Action:reiterated
Date:07/08/26

The score is held back mainly by weak technical momentum and a deteriorating operating trend, including declining revenue and compressing margins. Valuation is a clear support because the P/E is low and the dividend yield is high, while the balance sheet and cash generation prevent the score from falling further.

Positive Factors
Conservative balance sheetModest debt-to-equity (≈0.27–0.33) and a conservatively positioned balance sheet provide a durable financial cushion. This reduces refinancing and solvency risk, supports operations through cycles, and leaves capacity to fund opportunistic investments or sustain distributions over the medium term.
Negative Factors
Declining revenue trendA multi-year top-line decline culminating in ~-13% in 2025 signals loss of scale and demand headwinds. Persistent revenue contraction reduces margin leverage, limits reinvestment capacity, and raises risk to earnings and dividend sustainability if the trend continues over coming quarters.

Bamboos Health Care Holdings Ltd (2293) vs. iShares MSCI Hong Kong ETF (EWH)

-40%-30%-20%-10%0%10%20%HK:2293-23.58%EWH+8.05%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
HKD 162.45M
Dividend Yield
9.88%
Average Volume (3M)
88.00K
Price to Earnings (P/E)
26.1
Beta (1Y)
0.25
Revenue Growth
-10.65%
EPS Growth
-64.30%
Country
Hong Kong
Employees
92
Sector
Industrials
Sector Strength
63
Industry
Staffing & Employment Services

Bamboos Health Care Holdings Ltd Business Overview & Revenue Model

Company Description

Bamboos Health Care Holdings Limited functions as an investment holding entity primarily dedicated to furnishing healthcare workforce solutions throughout Hong Kong. Its extensive array of services includes vital support for medical facilities and ta...

How the Company Makes Money

null

Bamboos Health Care Holdings Ltd Financial Statement Overview

Summary

Financials are mixed: the balance sheet is relatively conservative with modest leverage, but revenue has declined for several years and margins have compressed. Cash flow remains positive, yet the trend is weakening, which keeps the overall financial profile below average despite continued profitability.

Income Statement

38Negative

Balance Sheet

72Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue66.44M66.71M74.40M94.79M126.56M140.29M
Gross Profit24.79M29.59M31.00M84.72M115.12M91.33M
EBITDA18.30M15.30M34.98M52.76M69.85M81.32M
Net Income6.24M6.24M17.54M30.92M46.92M58.62M
Balance Sheet
Total Assets325.22M325.22M315.90M318.06M346.83M351.35M
Cash, Cash Equivalents and Short-Term Investments35.33M35.33M52.96M81.15M93.27M86.27M
Total Debt58.71M58.71M62.13M63.73M68.24M68.96M
Total Liabilities77.88M77.88M86.54M99.74M124.51M140.75M
Stockholders Equity247.34M247.34M229.36M218.33M222.32M210.60M
Cash Flow
Free Cash Flow6.92M035.03M35.75M41.67M100.37M
Operating Cash Flow6.92M036.84M37.41M41.94M116.11M
Investing Cash Flow-2.72M0-51.58M-7.09M6.92M-111.63M
Financing Cash Flow-8.73M0-22.82M-42.44M-41.80M25.15M

Bamboos Health Care Holdings Ltd Technical Analysis

Technical Analysis SentimentNegative
Last Price0.41

Price Trends

50DMA0.39Positive
100DMA0.39Positive
200DMA0.41Negative

Market Momentum

MACD0.01Positive
RSI48.18Neutral
STOCH68.89Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2293, the sentiment is Negative. The current price of 0.41 is below the 20-day moving average (MA) of 0.41, above the 50-day MA of 0.39, and below the 200-day MA of 0.41, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 48.18 is Neutral, neither overbought nor oversold. The STOCH value of 68.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2293.

Bamboos Health Care Holdings Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (63)

Financial Indicators

HK:2293 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *63Neutral$10.79B15.437.44%2.01%2.89%-14.66%
HK:2135HK:213555NeutralHKD 62.39M3.9412.17%―36.68%―
HK:2293HK:229351NeutralHKD 163.00M26.132.49%9.88%-10.65%-64.30%
HK:6639HK:663948NeutralHKD 1.03B30.991.27%―――
HK:0722HK:072242NeutralHKD 292.35M-3.79-10.76%9.04%-1.37%-334.69%
HK:3886HK:388641NeutralHKD 1.10B78.090.48%1.10%-3.26%―
HK:8307HK:830737UnderperformHKD 60.30M64.2819.79%―6.13%―

* Industrials Sector Average

Performance Comparison

-40%-20%0%20%40%HK:2293HK:2135HK:3886HK:6639HK:0722HK:8307Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
HK:2293 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:2293Bamboos Health Care Holdings Ltd0.41-0.13-23.58%
HK:2135Raily Aesthetic Medicine International Holdings Limited0.11-0.01-5.88%
HK:3886Town Health International Medical Group Ltd.0.16-0.11-40.07%
HK:6639Arrail Group Ltd.1.83-0.12-6.21%
HK:0722UMP Healthcare Holdings Limited0.36-0.08-17.61%
HK:8307Medicskin Holdings Ltd.0.15-0.05-23.62%

Bamboos Health Care Holdings Ltd Corporate Events

Bamboos Health Care Announces Resignation of Executive Director

May 22, 2026

Bamboos Health Care Holdings Ltd has announced that executive director Mr. Cheng Sau Kong will resign from the board with effect from 22 May 2026. The company said Mr. Cheng is stepping down to focus on other engagements and business commitments, and...

Bamboos Health Care Revamps Board and Committee Roles Effective May 2026

May 22, 2026

Bamboos Health Care Holdings Limited has updated the composition of its board of directors effective 22 May 2026, confirming Ms. Hai Hiu Chu as executive director, chairman and chief executive officer, supported by three independent non-executive dir...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Jul 08, 2026